Literature DB >> 2261284

Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography.

M Tovi1, A Lilja, M Bergström, A Ericsson, K Bergström, M Hartman.   

Abstract

Fourteen patients with cerebral gliomas were investigated by MR imaging using Gd-DTPA (Magnevist), CT with the contrast agent iohexol (Omnipaque) and, as a reference, positron emission tomography (PET) using 11C-L-methionine. Tumour areas with disruption of the blood-brain-barrier (BBB) as seen on MR and CT were compared with areas increased accumulation of methionine in PET. There were 6 patients with high-grade astrocytoma (grade III-IV), 5 with low-grade astrocytoma (grade I-II) and 3 with oligodendroglioma. In 4 high-grade tumours, PET showed a larger tumour or tumour tissue in additional areas, compared with enhancement on MR and CT, while in 2 cases the tumour extension was similar in the three modalities. In the low grade tumour group, the findings on PET differed from those on post-contrast MR or CT in 7 cases. In 3 of these cases, no disruption of the BBB was seen either on MR or on CT. In 2 of our 14 patients CT showed larger enhancement extension than MR and in 2 cases MR was superior to CT in this respect. The enhancement intensity was higher on MR in 4 patients and on CT in 2 patients. No definite difference in the delineation of tumour tissue between the T1 weighted SE sequences was found. The gradient echo sequences FLASH and FISP gave limited information that was less than that provided by the T1 weighted SE sequences. A greater increase in signal intensity in T1 weighted images was usually seen 5 min post-contrast in the high-grade tumours than in the low-grade ones.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2261284

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  11 in total

1.  Value of 123I-IMT SPECT for diagnosis of recurrent non-astrocytic intracranial tumours.

Authors:  Michail Plotkin; Holger Amthauer; Julia Eisenacher; Reinhard Wurm; Roger Michel; Peter Wust; Florian Stockhammer; Rainer Röttgen; Matthias Gutberlet; Juri Ruf; Roland Felix
Journal:  Neuroradiology       Date:  2005-01-04       Impact factor: 2.804

2.  Detection of histological anaplasia in gliomas with oligodendroglial components using positron emission tomography with (18)F-FDG and (11)C-methionine: report of two cases.

Authors:  Shigeru Yamaguchi; Hiroyuki Kobayashi; Kenji Hirata; Tohru Shiga; Shinya Tanaka; Junichi Murata; Shunsuke Terasaka
Journal:  J Neurooncol       Date:  2010-06-15       Impact factor: 4.130

3.  Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis.

Authors:  Shingo Yonezawa; Kazuhiro Miwa; Jun Shinoda; Yuichi Nomura; Yoshitaka Asano; Noriyuki Nakayama; Naoyuki Ohe; Hirohito Yano; Toru Iwama
Journal:  J Neurooncol       Date:  2014-05-01       Impact factor: 4.130

4.  Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas.

Authors:  Norbert Galldiks; Lutz W Kracht; Lothar Burghaus; Anne Thomas; Andreas H Jacobs; Wolf-Dieter Heiss; Karl Herholz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-01       Impact factor: 9.236

5.  Evaluation of brain tumors using dynamic 11C-methionine-PET.

Authors:  Tatsuki Aki; Noriyuki Nakayama; Shingo Yonezawa; Syunsuke Takenaka; Kazuhiro Miwa; Yoshitaka Asano; Jun Shinoda; Hirohito Yano; Toru Iwama
Journal:  J Neurooncol       Date:  2012-04-22       Impact factor: 4.130

6.  Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme.

Authors:  Norbert Galldiks; Roland Ullrich; Michael Schroeter; Gereon R Fink; Andreas H Jacobs; Lutz W Kracht
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

7.  Contributions of biological tumor parameters to the incorporation rate of L: -[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas.

Authors:  Takeko Nojiri; Tadashi Nariai; Masaru Aoyagi; Michio Senda; Kenji Ishii; Kiichi Ishiwata; Kikuo Ohno
Journal:  J Neurooncol       Date:  2008-12-20       Impact factor: 4.130

8.  Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study.

Authors:  K Miwa; J Shinoda; H Yano; A Okumura; T Iwama; T Nakashima; N Sakai
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

Review 9.  Usefulness of FMISO-PET for glioma analysis.

Authors:  Hiroyuki Kobayashi; Kenji Hirata; Shigeru Yamaguchi; Shunsuke Terasaka; Tohru Shiga; Kiyohiro Houkin
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-10-29       Impact factor: 1.742

10.  Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen.

Authors:  N Galldiks; R Ullrich; M Schroeter; G R Fink; L W Kracht
Journal:  J Neurooncol       Date:  2009-01-29       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.